Merck & Co. Files 8-K on Financial Instruments

TL;DR

Merck filed an 8-K on 12/4/25 detailing its common stock and various notes due up to 2054.

AI Summary

On December 4, 2025, Merck & Co., Inc. filed an 8-K report detailing various financial instruments, including common stock and several series of notes due between 2026 and 2054. The filing indicates these instruments were active as of the reporting date.

Why It Matters

This filing provides insight into Merck's outstanding debt and equity, which are key components of its capital structure and financial health.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial instruments and does not indicate any immediate operational or financial distress.

Key Numbers

• 2026 — First Note Maturity (Indicates the earliest maturity date for a series of notes filed.)
• 2054 — Last Note Maturity (Indicates the latest maturity date for a series of notes filed.)
• 2025-12-04 — Filing Date (The date Merck & Co., Inc. submitted this current report.)

Key Players & Entities

• Merck & Co., Inc. (company) — Filer of the 8-K report
• 0000310158 (company) — Central Index Key for Merck & Co., Inc.
• December 4, 2025 (date) — Date of the earliest event reported
• 1.875% Notes Due 2026 (dollar_amount) — Specific debt instrument mentioned
• 3.250% Notes Due 2032 (dollar_amount) — Specific debt instrument mentioned
• 2.500% Notes Due 2034 (dollar_amount) — Specific debt instrument mentioned
• 1.375% Notes Due 2036 (dollar_amount) — Specific debt instrument mentioned
• 3.500% Notes Due 2037 (dollar_amount) — Specific debt instrument mentioned
• 3.700% Notes Due 2044 (dollar_amount) — Specific debt instrument mentioned
• 3.750% Notes Due 2054 (dollar_amount) — Specific debt instrument mentioned

FAQ

Key Financial Figures

• $0.50 — ange on which registered Common Stock ($0.50 par value) MRK New York Stock Exchange
• $500,000,000 — osed an underwritten public offering of $500,000,000 aggregate principal amount of Floating
• $750,000,000 — s due 2029 (the "Floating Rate Notes"), $750,000,000 aggregate principal amount of 3.850% No
• $1,000,000,000 — 850% Notes due 2029 (the "2029 Notes"), $1,000,000,000 aggregate principal amount of 4.150% No
• $1,500,000,000 — 450% Notes due 2032 (the "2032 Notes"), $1,500,000,000 aggregate principal amount of 4.750% No

Filing Documents

• mrk-20251204.htm (8-K) — 44KB
• exhibit41-closing8xk.htm (EX-4.1) — 162KB
• exhibit42-closing8xk.htm (EX-4.2) — 98KB
• exhibit43-closing8xk.htm (EX-4.3) — 97KB
• exhibit44-closing8xk.htm (EX-4.4) — 99KB
• exhibit45-closing8xk.htm (EX-4.5) — 88KB
• exhibit46-closing8xk.htm (EX-4.6) — 98KB
• exhibit47-closing8xk.htm (EX-4.7) — 88KB
• exhibit48-closing8xk.htm (EX-4.8) — 97KB
• exhibit51-closing8xk.htm (EX-5.1) — 11KB
• formula.jpg (GRAPHIC) — 12KB
• 0001628280-25-055388.txt ( ) — 1250KB
• mrk-20251204.xsd (EX-101.SCH) — 4KB
• mrk-20251204_def.xml (EX-101.DEF) — 18KB
• mrk-20251204_lab.xml (EX-101.LAB) — 33KB
• mrk-20251204_pre.xml (EX-101.PRE) — 19KB
• mrk-20251204_htm.xml (XML) — 8KB

01 Other Events

Item 8.01 Other Events. On December 4, 2025, Merck & Co., Inc. (the "Company") closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2029 (the "Floating Rate Notes"), $750,000,000 aggregate principal amount of 3.850% Notes due 2029 (the "2029 Notes"), $1,000,000,000 aggregate principal amount of 4.150% Notes due 2031 (the "2031 Notes"), $1,000,000,000 aggregate principal amount of 4.450% Notes due 2032 (the "2032 Notes"), $1,500,000,000 aggregate principal amount of 4.750% Notes due 2035 (the "2035 Notes"), $750,000,000 aggregate principal amount of 5.500% Notes due 2046 (the "2046 Notes"), $1,500,000,000 aggregate principal amount of 5.550% Notes due 2055 (the "2055 Notes") and $1,000,000,000 aggregate principal amount of 5.700% Notes due 2065 (the "2065 Notes" and, together with the Floating Rate Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2035 Notes, the 2046 notes and the 2055 Notes, collectively, the "Notes") under the Company's Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the "Commission") on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024. The Notes are being issued under an indenture dated as of January 6, 2010, between the Company and U.S. Bank Trust National Association, as trustee, a copy of which was attached as Exhibit 4.1 to the Company's Current Report on Form 8-K previously filed with the Securities and Exchange Commission on December 10, 2010 and is incorporated herein by reference. Copies of the officers' certificate for each series of the Notes (including forms of each of the respective Notes attached thereto) pursuant to Section 301 of the indenture governing the Notes are attached hereto as Exhibits 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7 and 4.8 and are incorporated herein by reference. The legal opinion related to these Notes is attached h

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 4.1 Floating Rate Notes due 2029 Officers' Certificate of the Company dated December 4, 2025, including form of the Floating Rate Notes. Exhibit 4.2 3.850% Notes due 2029 Officers' Certificate of the Company dated December 4, 2025, including form of the 2029 Notes. Exhibit 4.3 4.150% Notes due 2031 Officers' Certificate of the Company dated December 4, 2025, including form of the 2031 Notes. Exhibit 4.4 4.450% Notes due 2032 Officers' Certificate of the Company dated December 4, 2025, including form of the 2032 Notes. Exhibit 4.5 4.750% Notes due 2035 Officers' Certificate of the Company dated December 4, 2025, including form of the 2035 Notes. Exhibit 4.6 5.500% Notes due 2046 Officers' Certificate of the Company dated December 4, 2025, including form of the 2046 Notes. Exhibit 4.7 5.550% Notes due 2055 Officers' Certificate of the Company dated December 4, 2025, including form of the 2055 Notes. Exhibit 4.8 5.700% Notes due 2065 Officers' Certificate of the Company dated December 4, 2025, including form of the 2065 Notes. Exhibit 5.1 Opinion and Consent of Jennifer Zachary, Esq., Executive Vice President and General Counsel of the Company. Exhibit 23.1 Consent of Jennifer Zachary, Esq., Executive Vice President and General Counsel of the Company (contained in Exhibit 5.1 to this Current Report on Form 8-K). Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 4, 2025 Merck & Co., Inc. By: /s/ Kelly E. W. Grez Kelly E. W. Grez Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR